Stockpolly
Search
Delisting risk
PPBT · NASDAQ · Biotechnology

Purple Biotech (ADR) (PPBT)

Develops CAPTN-3 tri-specific cancer antibodies and other oncology drug candidates.

$1.85
Pre-market−0.13 (−6.33%)
At close$1.98(+18.98%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
6643211112321
Research & development553210111211
Selling, general & administrative111110111111
Other expenses0000000002100
Operating income−6−6−4−3−2−1−1−1−1−23−2−1
111111100022
Interest income100000000000
Interest expense020010000000
Other non-operating income−10−1−1−20−1000−2−2
Income before tax−5−5−4−2−100−1−1−2400
Net income from continuing operations−5−5−4−2−100−1−1−2400
Net income−5−5−4−2−100−1−1−2400
EPS, basic−$46.20−$3.74−$2.78−$1.74−$0.38−$0.20−$0.18−$0.40−$0.28−$1.98$0.00$0.04
EPS, diluted−$46.20−$3.78−$2.78−$1.74−$0.38−$0.20−$0.18−$0.40−$0.28−$1.98$0.00$0.04
Weighted average shares, basic01112233512911
Weighted average shares, diluted01112233512911
EBITDA−5−6−4−20−10−1−1−2401
Depreciation & amortization000000000000
EBIT−5−6−4−20−10−1−1−2400